Stock Analysis
Idexx Laboratories IncIDXX
P/E 38.74×· 5Y range 33.05–81.40×· bottom 6% of history
Sector: Healthcare · Industry: In Vitro & In Vivo Diagnostic Substances
AnalystsBuy22 analystsP/E 38.7× sits at the 6th percentile of its 5.086926762491444-year history.
Cash covers 18% of debt · Q2 2026.
PMP Verdict
Strong business, attractive price
Strengths
- Profitability100
- Quality95
High-quality business at an attractive price.
Market context
+2.4% today· Z 1.3σ
Bull Case
- ✓Piotroski F-Score 8/9 — high earnings quality
- ✓Altman Z 19.0 — safe-zone balance sheet
- ✓ROE 70.7% — efficient capital deployment
- ✓Interest coverage 37.8× — debt well covered
- ✓P/E 38.7× at bottom 6% of 5-year history
What's happening with IDXX
Profile
Strong profitability, moat and earnings quality; valuation lags behind.
How is each axis scored?
- Valuation47/100 · Weak
- P/E vs own history (6th pct)25/25
- FCF yield (2.8%)5/25
- P/S (9.7x)12/25
- EV/EBIT (30.9x)5/25
- Growth64/100 · Moderate
- Revenue CAGR (7.6%)12/25
- Net income CAGR (9.2%)12/25
- EPS CAGR 5Y (11.0%)20/25
- Fwd implied growth (20.3%)20/25
- Profitability100/100 · Strong
- ROIC (45.9%)25/25
- ROE (70.7%)25/25
- Net margin (25.0%)25/25
- Operating margin (32.0%)25/25
- Financial Health74/100 · Moderate
- Altman Z (19.02)25/25
- Current ratio (1.17)12/25
- Interest coverage (37.8x)25/25
- Net cash / debt (D/A 26%)12/25
- Quality95/100 · Strong
- Piotroski F (8/9)25/25
- Beneish M (-2.58)25/25
- FCF conversion (110%)25/25
- Margin stability (σ 5.2%)20/25
- Moat100/100 · Strong
- ROIC >12% years (10/10 yrs)25/25
- Median gross margin (58.4%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 12.5%)25/25
About Idexx Laboratories Inc
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Show more
Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Headquarters: WESTBROOK, ME · Employees: 11,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
47D+P/E (TTM)38.7xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 33.0x–81.4x · 6th pct
P/FCF34.6xC
Grade C: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield2.8%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 1.0%–3.1% · 96th pct
P/S (TTM)9.70xC
Grade C: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 7.5x–19.4x · 21st pct
EV/EBIT30.9xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 26.1x–69.2x · 6th pct
EV/Sales9.6xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E32.2xC
Grade C: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio27.38xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio2.78C
Grade C: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
100A+ROIC45.9%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE70.7%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA33.6%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin25.0%A
Grade A: HighNet Income / Revenue
Operating Margin32.0%A
Grade A: HighTTM EBIT / TTM Revenue
Gross Margin62.4%A
Grade A: PremiumGross Profit / Revenue
FCF Margin27.5%A
Grade A: HighFCF / Revenue
True FCF Margin26.2%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
64BRevenue CAGR7.6%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR9.2%C
Grade C: OkCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)11.0%C
Grade C: OkCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth20.3%C
Grade C: MedAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-9.2%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income5.5%A
Grade A: LowStock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.4%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
74B+Altman Z-Score19.02A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.17xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio0.82xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage37.8xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt Repayment0.7yA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT0.6xA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.68xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.18xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
95A+Piotroski F-Score8/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.58A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion110.1%A
Grade A: StrongFCF / Net Income
Margin Stability5.2%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue2.6%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover1.34xA
Grade A: HighRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Kingsley Lawrence D Filed | Kingsley Lawrence D | Option exercise | -2203 | |
Kingsley Lawrence D Filed | Kingsley Lawrence D | SellOpen market sale | -2203 | |
Kingsley Lawrence D Filed | Kingsley Lawrence D | Option exercise | +2.2K | |
Emerson Andrew Filed | Emerson Andrew | Option exercise | -265 | |
Emerson Andrew Filed | Emerson Andrew | Tax withholding | -86 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Emerson Andrew Filed | Emerson Andrew | Option exercise | +265 | |
HOOLEY JOSEPH L Filed | HOOLEY JOSEPH L | Grant / award | +49 | |
FENNELL GEORGE Filed | FENNELL GEORGE | Option exercise | -639 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
100A+ROIC >12% Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)58.4%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor12.5%A
Grade A: DurableWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$14.47
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$2.50
Cash & short-term investments per share (Finnhub)
Book Value / Share$20.45
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$1.10B
Total debt obligations (short + long term)
Cash & Equiv.$196.93M
Cash and short-term investments
Net Debt$899.15M
Total Debt minus Cash. Negative = Net Cash position
Total Equity$1.61B
Shareholders' equity (book value)
Asset / Liability1.88xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$44.15B
Current Market Capitalization
Beta1.56C
Grade C: VolatilePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Idexx Laboratories Inc (IDXX)
IDXX is up 2.41% at the last close. Idexx Laboratories Inc meets 8 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 19.02 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.58 suggests a low likelihood of earnings manipulation.
- Idexx Laboratories Inc converts about 28% of revenue into free cash flow — strong cash generation.
- Takes ~0.7 years to repay net debt from free cash flow.
- Return on equity of 70.7% is well above the market average.
See how IDXX ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all IDXX moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Regular | 545.71 | +3.16% | 2.17 |
| Oct 15 | After-hours | 547.18 | +3.43% | 2.38 |
Frequently Asked Questions about IDXX
What is the current Idexx Laboratories Inc (IDXX) stock price?
IDXX is trading at $560.36 at the last market close, up 2.41% on the session. PreMarketPrice tracks IDXX pre-market, intraday and after-hours prices.
Is IDXX stock a buy right now?
PreMarketPrice's quantitative model rates Idexx Laboratories Inc's financial health at 74/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is IDXX stock overvalued?
Idexx Laboratories Inc trades at a trailing P/E of 38.7 and our valuation score rates it 47/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Idexx Laboratories Inc report earnings?
No confirmed earnings date is currently scheduled for IDXX. The Earnings section lists recent reports and updates as dates are announced.
What sector does Idexx Laboratories Inc operate in?
Idexx Laboratories Inc operates in the Healthcare sector, within the In Vitro & In Vivo Diagnostic Substances industry. The Related Stocks section lists sector peers for comparison.
What does Idexx Laboratories Inc do?
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock.
About Idexx Laboratories Inc (IDXX) Stock
Idexx Laboratories Inc (IDXX) is a US-listed stock operating in the Healthcare sector, specifically the In Vitro & In Vivo Diagnostic Substances industry. As of the latest update, Idexx Laboratories Inc is trading at $560.36, up 2.41% on the day with a market capitalization of $44.1 billion. The financial health score for IDXX is 74/100, which indicates good financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for IDXX stock.
IDXX Stock Analysis & Key Metrics
On PreMarketPrice, you can track Idexx Laboratories Inc (IDXX) across multiple dimensions:
- Pre-market price & movement: Real-time IDXX stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for IDXX with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Idexx Laboratories Inc across multiple reporting periods.
- Financial health score: A composite score of 74/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for IDXX.
- Sector peers: Compare IDXX against 4 other healthcare stocks on key financial metrics.
Is IDXX a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Idexx Laboratories Inc (IDXX) as an investment. The financial health score of 74/100 suggests good financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Idexx Laboratories Inc (IDXX) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.